Get the Stockscreener App
0.72
14.14%
-0.1186
After Hours:
.71
-0.01
-1.39%
BiomX Inc stock is traded at $0.72, with a volume of 401.74K.
It is down -14.14% in the last 24 hours and up +5.88% over the past month.
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$0.8386
Open:
$0.8084
24h Volume:
401.74K
Relative Volume:
0.08
Market Cap:
$7.31M
Revenue:
-
Net Income/Loss:
$-47.68M
P/E Ratio:
-0.0288
EPS:
-24.9619
Net Cash Flow:
$-23.09M
1W Performance:
-42.86%
1M Performance:
+5.88%
6M Performance:
-86.07%
1Y Performance:
-92.27%
1-Day Range:
$0.705
$0.81
1-Week Range:
$0.705
$1.16
52-Week Range:
$0.3608
$14.71
BiomX Inc Stock (PHGE) Company Profile
Name
BiomX Inc
Sector
Industry
Phone
972 7 23942377
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Compare PHGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.72 | 8.51M | 0 | -47.68M | -23.09M | -24.96 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-21 | Initiated | Ladenburg Thalmann | Buy |
BiomX Inc Stock (PHGE) Latest News
BiomX Inc. Enters Line of Credit Agreement and Issues 12% Convertible Promissory Note – SEC 8-K Filing June 2026 - Minichart
BiomX subsidiary launches mobile command app for operators - Investing.com
BiomX Issues Restricted Shares Under Mandragola Credit Facility - TipRanks
BiomX (NYSE: PHGE) converts debt to shares and grants 2M-share warrant - Stock Titan
PHGE - Finviz
BiomX Inc. Appoints Former Elbit Systems Chief Scientist Gabby Sarusi to Board of Directors - geneonline.com
BiomX announces CEO and board changes, appoints Michael Oster as chief executive - Investing.com
BiomX Inc. Appoints Prof. Gabby Sarusi as Strategic Advisor to Enhance Defense and Security Capabilities - Moomoo
Ex-Elbit defense scientist joins BiomX push into threat-detection tech - Stock Titan
BiomX Company Profile & Introduction - Moomoo
BiomX expands Zorronet's AI C5ISR suite for secure on-premise defense and critical infrastructure use. - Pluang
Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence - The Manila Times
AI security system moves on-site: no public cloud for hardened facilities - Stock Titan
PHGE Q4 2025 Earnings: EPS Miss of -$8.17 Amid Continued Clinical DevelopmentEarnings Call Transcript - thelegaladvocate.com
BiomX Appoints Roy Rousso as Chief Business Officer - The Globe and Mail
PHGE Stock Price, Quote & Chart | BIOMX INC (NYSEARCA:PHGE) - ChartMill
Deerfield funds report 8.09% BiomX (PHGE) ownership after warrant and preferred conversions - Stock Titan
BiomX Inc. Appoints Roy Rousso as Chief Business Officer Effective July 1, 2026 – Details of Consulting Agreement - Minichart
BiomX appoints Roy Rousso as Chief Business Officer - TradingView
BiomX (NYSE: PHGE) hires Roy Rousso as new Chief Business Officer - Stock Titan
BiomX Inc. (PHGE) Q4 2025 Earnings: EPS Misses by Wide Margin, No Revenue, Stock DeclinesEarnings Quality Analysis - The Legal Advocate
BiomX (PHGE) Appoints New Chief Business Officer to Strengthen L - GuruFocus
BiomX appoints Roy Timor-Rousso as chief business officer By Investing.com - Investing.com India
BiomX Inc. (PHGE) Slides 7%: Crucial Support Test Nears as Selling Pressure IntensifiesGrowth Factor - The Legal Advocate
BiomX (PHGE) Appoints New Chief Business Officer to Strengthen Leadership - GuruFocus
BiomX appoints Roy Timor-Rousso as chief business officer - Investing.com
BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations - marketscreener.com
BiomX Inc. Announces the Appointment of Roy Timor-Rousso as Chief Business Officer - marketscreener.com
PHGE Stock Jumps As BiomX Launches AI Command App - StocksToTrade
PHGE Stock Pops As BiomX Unveils AI Command App - timothysykes.com
BiomX Inc. (PHGE) Surges 10.5%: Can the Rally Hold Above $0.78 Support?Point of Control - Newser
PHGE Q4 2025 Earnings: EPS Misses Estimates Significantly, Stock Rises 10.5%Profit Margin Analysis - newsline.com
PHGE Q4 2025 Earnings: Severe EPS Miss as BiomX Continues Clinical DevelopmentSmart Trader Community - Newser
BiomX Inc. (PHGE) Q4 2025 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineInvestment Community - Newser
BiomX Inc. Q4 2025 Earnings: Large Earnings Miss Stirs Uncertainty, No Revenue ReportedEPS Estimate Trend - newsline.com
BiomX Inc. (PHGE) Q4 2025 Profit Warning: EPS $-8.17 Trails $-4.70Tangible Book Value - Newser
BiomX Inc. 1Q 2026: Net income $(19.14M), EPS $(7.38) — 10-Q Summary - TradingView
PHGE: Q1 2026 net loss was $19.1M amid a strategic pivot to defense and security tech - TradingView
BiomX (NYSE American: PHGE) pivots to defense tech amid Q1 2026 loss and going-concern risk - Stock Titan
BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BiomX Inc. (PHGE) Jumps 6.1% as Earnings Loom Thursday - Meyka
BiomX Inc. (PHGE) Q4 2025 Disappoints — EPS $-8.17 Below $-4.70 ViewsCommunity Breakout Alerts - Newser
PHGE Should I Buy - Intellectia AI
BiomX Delays Quarterly Report Amid Strategic Shift - The Globe and Mail
BiomX Inc. (PHGE) Stock Analysis: Falls -9.02%, Watching $0.50 2026-05-15Stock Community Signals - Newser
[NT 10-Q] BiomX Inc. SEC Filing - Stock Titan
BiomX Inc Stock (PHGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
BiomX Inc Stock (PHGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yeganeh Reuven | Director |
Mar 16 '26 |
Sale |
5.00 |
450,000 |
2,250,000 |
0 |
| Yeganeh Reuven | Director |
Mar 13 '26 |
Sale |
5.00 |
370,000 |
1,850,000 |
0 |
| Yeganeh Reuven | Director |
Mar 12 '26 |
Sale |
5.00 |
300,000 |
1,500,000 |
0 |
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):